About OptiKira

About company

OptiKira develops novel therapeutics intended to prevent cell death. It targets UPR and regulates its activity to prevent cell degeneration in idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, diabetes, cancer,, and various neurodegenerative diseases, enabling medical practitioners to treat Retinitis pigmentosa, amyotrophic lateral sclerosis, and other chronic diseases. OptiKira was founded in 2014 and is headquartered in Cleveland, Ohio.